What Unlimited Bio does

Unlimited Bio is a privately held longevity biotechnology company founded in 2024 and registered in Próspera ZEDE, Roatán, Honduras. The company develops combinatorial gene therapies targeting multiple aging-related biological pathways simultaneously, with a current product portfolio anchored on two modalities: VEGF165 plasmid gene therapy (sourced from Artgen Biotech's Neovasculgen, with a 12+ year safety record from over 10,000 patients) and AAV9-Follistatin gene therapy (licensed from BioViva), targeting angiogenesis, muscle growth, and vascular rejuvenation. Pipeline candidates include Klotho (longevity-associated protein) and BDNF (neurotrophic factor), which are being explored in mouse trials as part of a four-gene cocktail. The company's flagship clinical program is CALM-AF-AI (NCT07443826), a Phase 1/2a trial it claims is the first registered study worldwide to combine AAV9-Follistatin with VEGF plasmid gene therapy.

The company operates a direct-to-consumer model in which prospective patients inquire via the website or scheduled calls, are screened for eligibility, and pay to receive investigational gene therapies at partner clinics in Special Economic Zones and Right-to-Try jurisdictions, specifically GARM Clinic in Roatán (Honduras), GARM Bahamas on Paradise Island, and partner clinics in Mexico. Unlimited Bio is structured as a facilitator rather than a medical provider, with therapies explicitly labeled experimental and not FDA-approved. The company is supported by an institutional strategic investment from Immortal Dragons (a Singapore-based $40 million longevity fund) and ecosystem backing from Infinita City.

Commercially, Unlimited Bio targets four primary segments: men with vasculogenic erectile dysfunction, peripheral artery disease (PAD) patients, adults with age-related muscle loss (sarcopenia), and longevity-focused early adopters/biohackers. Indications extend to androgenetic alopecia (hair regrowth). Its go-to-market relies heavily on earned media (MIT Technology Review, Longevity.Technology), longevity-conference circuit presence (RAADfest, ARDD Copenhagen, Vitalist Bay, Revive ME Abu Dhabi), and community channels including podcasts (Optispan with Dr. Matt Kaeberlein, Infinita City, Meet the Drapers). The company's stated long-term ambition is to execute 100 clinical or real-world trials within 10 years using a combination-therapy framework.

Name

Unlimited Bio

Legal name

Unlimited Bio Company

Website

https://unlimited.bio

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Unlimited Bio is a private longevity biotech founded in 2024 in Próspera ZEDE, Honduras, developing combinatorial gene therapies (VEGF plasmid, AAV9-Follistatin, plus Klotho/BDNF pipeline) and delivering them through partner clinics to affluent early-adopter patients seeking vascular, muscle, and systemic rejuvenation.

Ownership category

akta.pro rank

Product category

Longevity gene therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)

akta.pro secondary industry

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Gene therapy development
• Longevity biotechnology
• Rejuvenation therapeutics
• Plasmid gene therapy
• Combinatorial gene therapy

Headquarters

HQ city

Roatán

HQ country

Honduras

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Gene Therapy Administration Services: Unlimited Bio provides access to its investigational gene therapies through partner clinics (GARM in Roatán, Honduras; GARM Bahamas; Mexico). Patients pay for treatment administration. The therapies are experimental and not FDA-approved; treatments are provided under Right-to-Try frameworks in Special Economic Zones. The company operates as a facilitator between patients and partner clinics rather than as a direct medical provider.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Unlimited Bio develops and facilitates access to investigational combinatorial gene therapies for age-related biological decline. Its core offerings are VEGF plasmid gene therapy (Neovasculgen) for vascular rejuvenation, hair regrowth, peripheral artery disease, and erectile dysfunction, and AAV9-Follistatin gene therapy for age-related muscle loss (sarcopenia). These therapies are delivered to patients at partner clinics in Special Economic Zones (Próspera ZEDE in Honduras, the Bahamas, and Mexico) under Right-to-Try frameworks, with the company acting as developer and facilitator rather than licensed medical provider.

Product overview

Unlimited Bio is a biotechnology company developing gene therapies for longevity and rejuvenation. The core product portfolio centers on VEGF (Vascular Endothelial Growth Factor) plasmid gene therapy and Follistatin AAV gene therapy, with pipeline candidates Klotho and BDNF. VEGF therapy is available across multiple indications: general vascular/muscle rejuvenation, peripheral artery disease (PAD), and erectile dysfunction. Follistatin targets muscle growth for age-related decline. The company is advancing a combination therapy strategy, with the CALM-AF-AI trial (first-in-human combination of AAV9-Follistatin + VEGF) as the flagship clinical program. Pipeline includes Klotho (anti-aging) and BDNF (cognitive enhancement), with an ambitious goal of 100 clinical trials in 10 years. Therapies are delivered at partner clinics in Próspera ZEDE (Roatán, Honduras), Mexico, and Bahamas.

Differentiator

Problem solved

Functional benefit

Products and services

• VEGF Gene Therapy Investigational VEGF (Vascular Endothelial Growth Factor) plasmid gene therapy delivered as local intramuscular or intratissue injection to stimulate angiogenesis, improve tissue oxygenation and nutrient delivery, and support vascular rejuvenation, muscle support, and hair growth. Available at partner clinics in Próspera ZEDE (Honduras), the Bahamas, and Mexico under Right-to-Try frameworks.
• VEGF for Peripheral Artery Disease (PAD) Indication-specific VEGF plasmid gene therapy (Neovasculgen) for peripheral artery disease, delivered as intramuscular injections into ischemic leg muscles to grow new blood vessels around blockages, restore circulation, and prevent amputation. For patients with intermittent claudication (Stage IIB), critical limb ischemia (Stage III/CLI), or diabetic circulation compromise.
• VEGF for Erectile Dysfunction Investigational VEGF plasmid gene therapy for erectile dysfunction, delivered via intracavernosal injections to regenerate blood vessels and repair endothelium in erectile tissue. Addresses vascular causes of ED (diabetes, atherosclerosis, hypertension, aging, post-prostatectomy nerve injury) rather than masking symptoms like PDE5 inhibitors.
• Follistatin AAV Gene Therapy AAV gene therapy delivering the follistatin gene (FS344 isoform) via intramuscular injection into target muscle. The episomal AAV9 vector blocks both myostatin and activin, lifting the two primary brakes on muscle growth, to address age-related muscle loss (sarcopenia) and performance enhancement. Trial recruitment is in progress through GARM Bahamas and partner clinics.
• Combination Therapy: Musculoskeletal Rejuvenation (Combination #1) Coordinated delivery of VEGF plasmid and Follistatin AAV gene therapies in a single protocol, simultaneously targeting capillary density (vascular rejuvenation) and muscle mass for comprehensive musculoskeletal rejuvenation. Part of Unlimited Bio's combination therapy platform addressing multifactorial aging.
• CALM-AF-AI Phase 1/2a Clinical Trial Participation Phase 1/2a open-label dose-escalation clinical trial (CALM-AF-AI, NCT07443826) evaluating AAV9-Follistatin gene therapy as standalone and combined with VEGF plasmid gene therapy for age-related muscle decline. Enrollment of approximately 12 adults aged 45–75 at GARM Clinic in Roatán, Honduras.

Quantifiable outcome

• +683% pain-free walking distance in Stage III PAD patients
• +6 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Oliver Zolman MD / XPRIZE HealthspancoreStrategic or Co-development Partner · 3 March 2026Unlimited Bio partnered with Dr. Oliver Zolman, a leading longevity physician and scientist, to build a one-year integrated rejuvenation protocol combining evidence-based lifestyle practices with investigational therapeutics, to compete in the $101M XPRIZE Healthspan competition. The protocol will include measurable biomarkers and combine best-practice approaches with frontier gene therapy innovation.
• BioVivacoreTechnology or Integration · 18 December 2024Unlimited Bio entered an exclusive license agreement with BioViva (led by longevity pioneer Liz Parrish) for four advanced AAV-mediated gene therapies targeting telomeres, muscle mass, systemic anti-aging factors, and mitochondrial health. BioViva has a track record of pioneering gene therapy administration, including Liz Parrish's self-administration of telomerase therapy in 2015. This collaboration is designed to fast-track UB's preventive gene therapy program into a cohesive clinical trial protocol.
• Artgen BiotechcoreTechnology or Integration · 13 May 2024Unlimited Bio partnered with Artgen Biotech, the manufacturer of the world's first approved VEGF plasmid gene therapy (Neovasculgen), to explore new applications of VEGF in cosmetic and regenerative medicine including skin vascularization, hair regrowth, and muscle rejuvenation.
• GARM CliniccoreChannel Partner/ Reseller/ DistributorGARM Clinic is Unlimited Bio's primary clinical partner, conducting gene therapy administrations and clinical trials in Próspera ZEDE (Roatán, Honduras). GARM also opened a flagship clinic in the Bahamas (Hurricane Hole Marina, Paradise Island) offering Unlimited Bio's VEGF therapy. GARM brings 12 years of legacy in regenerative medicine, with a team of physicians including Dr. Robin Roberts, Dr. Glenn C. Terry, Dr. Douglas Tucker, Dr. Dane Bowe, Dr. Mikhail Higgins, and Dr. Roddy McGee.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Rejuvenate Bio: Rejuvenate Bio develops gene therapies targeting age-related diseases in dogs and humans, co-founded by George Church. Comparable as an AAV-based longevity gene therapy company at similar early stage, though focused on partial reprogramming rather than combinatorial gene cocktails.
• Longeveron: Longeveron is a clinical-stage cell therapy company developing therapies for aging-related frailty and hypoplastic left heart syndrome. Comparable as a public longevity biotech with age-related clinical indications, though using cell therapy rather than gene therapy.
• Loyal for Dogs (Loyal): Loyal develops FDA-conditional drugs to extend dog lifespan, and is the most credible longevity drug developer with regulatory progress. Comparable in targeting aging biology commercially but via small-molecule drugs rather than gene therapy.

Direct peers

• BioAge Labs: BioAge Labs is a clinical-stage biotech developing therapeutics targeting the molecular mechanisms of aging and was also a Top 100 XPRIZE Healthspan team. It competes for the same longevity/biotech capital and target patient demand for aging therapeutics.
• BioViva: BioViva is Unlimited Bio's exclusive licensor for four AAV gene therapies (telomerase, follistatin, klotho, mitochondrial). Liz Parrish pioneered self-administration of telomerase gene therapy in 2015 and BioViva operates in the same longevity AAV gene therapy category, making it the closest direct comparable.
• Unity Biotechnology: Unity Biotechnology develops senolytic therapeutics to clear senescent cells and treat age-related diseases. Comparable as a clinical-stage longevity biotech targeting systemic aging biology, though via small molecules rather than gene therapy.
• Minicircle: Minicircle develops plasmid and gene therapy protocols for human enhancement and longevity, and like Unlimited Bio operates from Próspera ZEDE in Roatán. They target overlapping biohacker/longevity customer segments using Right-to-Try frameworks in SEZs.
• Artgen Biotech: Artgen manufactures Neovasculgen, the world's first approved VEGF plasmid gene therapy (used in 10,000+ PAD patients). Unlimited Bio licenses/manufactures through Artgen for cosmetic and regenerative applications, making it both partner and direct comparable in VEGF plasmid commercialization.

Broad incumbents

• Altos Labs: Altos Labs is a well-funded ($3B+) cellular reprogramming biotech focused on restoring cell health and reversing disease. It targets the same healthspan/longevity opportunity at far greater scale and with broader scientific reach.
• Insilico Medicine: Insilico Medicine is a leading AI-driven drug discovery company with a major longevity pipeline, including IPF and aging-related programs. It competes for longevity-focused capital and pharma partnerships at a much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/UnlimitedBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unlimited Bio